Tracey Beth Høeg was named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), marking another rapid leadership change at the agency and fueling industry concern about regulatory direction. Commentators tied Høeg’s appointment to evolving vaccine policy debates and to a broader reorganization at FDA centers, noting potential impacts on vaccine and drug review pathways. Analysts and former FDA leaders warned of staff departures and shifts in review expectations that could affect timelines for drug approvals. This leadership change occurs alongside public disputes over vaccine guidance and proposals to alter approval standards.